Patients with type 1 diabetes who used the Medtronic MiniMed 670G, a hybrid closed-loop system, had their average A1C reduced by 0.9% from baseline to 6 months and by 1.2% from baseline to 12 months, according to findings presented at the American Association of Diabetes Educators annual meeting. Researchers surveyed 33 adults and found that participants also experienced time-in-range benefits and reported an average satisfaction score of 3.79 out of 5.
Medtronic's MiniMed shows promise for reducing A1C in diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.